Xiaojuan Zhang

Xiaojuan Zhang

Auto-generated profile, based on publicly available information

Xiaojuan Zhang

Department of Cell Biochemistry, University of Groningen

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
XZXiaojuan Zhang
Xiaojuan Zhang
Arjan KortholtArjan Kortholt
Arjan Kortholt
Mutations in the multidomain protein Leucine-rich-repeat kinase 2 (LRRK2) have been identified as a genetic risk factor for both sporadic and familial Parkinson’s disease (PD). LRRK2 has two enzymatic domains: a RocCOR tandem with GTPase activity and a kinase domain. In addition, LRRK2 has three N-terminal domains: ARM (Armadillo repeat), ANK (Ankyrin repeat), and LRR (Leucine-rich-repeat), and a C-terminal WD40 domain, all of which are involved in mediating protein–protein interactions (PPIs) and regulation of the LRRK2 catalytic core. The PD-related mutations have been found in nearly all LRRK2 domains, and most of them have increased kinase activity and/or decreased GTPase activity. The complex activation mechanism of LRRK2 includes at least intramolecular regulation, dimerization, and membrane recruitment. In this review, we highlight the recent developments in the structural characterization of LRRK2 and discuss these developments from the perspective of the LRRK2 activation mechanism, the pathological role of the PD mutants, and therapeutic targeting.

18 May 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
PPPragya Pathak
Pragya Pathak
KAKrista K. Alexander
Krista K. Alexander
LHLeah G. Helton
Leah G. Helton
MKMichalis Kentros
Michalis Kentros
TLTimothy J. LeClair
Timothy J. LeClair
EKEileen J. Kennedy
Eileen J. Kennedy
Missense mutations along the leucine-rich repeat kinase 2 (LRRK2) protein are a major contributor to Parkinson's Disease (PD), the second most commonly occurring neurodegenerative disorder worldwide. We recently reported the development of allosteric constrained peptide inhibitors that target and downregulate LRRK2 activity through disruption of LRRK2 dimerization. In this study, we designed doubly constrained peptides with the objective of inhibiting C-terminal of Roc (COR)-COR mediated dimerization at the LRRK2 dimer interface. We show that the doubly constrained peptides are cell-permeant, bind wild-type and pathogenic LRRK2, inhibit LRRK2 dimerization and kinase activity, and inhibit LRRK2-mediated neuronal apoptosis, and in contrast to ATP-competitive LRRK2 kinase inhibitors, they do not induce the mislocalization of LRRK2 to skein-like structures in cells. This work highlights the significance of COR-mediated dimerization in LRRK2 activity while also highlighting the use of doubly constrained peptides to stabilize discrete secondary structural folds within a peptide sequence.

11 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
GGGiambattista Guaitoli
Giambattista Guaitoli
XZXiaojuan Zhang
Xiaojuan Zhang
FSFrancesca Saitta
Francesca Saitta
PMPasquale Miglionico
Pasquale Miglionico
LSLaura M. Silbermann
Laura M. Silbermann
CGChristian Johannes Gloeckner
Christian Johannes Gloeckner
Leucine-rich repeat kinase 2 (LRRK2) is a large, multi-domain protein which is associated with Parkinson’s disease. Although high-resolution structures of LRRK2 are available, little is known about the complex dynamics behind the inter-domain regulation of LRRK2 and its perturbation by pathogenic variants. Previous studies have demonstrated that LRRK2 goes through an oligomerization cycle at the membrane, however it remains unclear in which form it exerts its kinase activity. Moreover, the LRRK2 monomer-dimer equilibrium and associated functional implications at a molecular level also need further investigation. In the present work, we used a multi-faceted approach to better understand LRRK2 oligomerization and suggest a functional model of how LRRK2 interacts with its substrates. To this end, we combined nano differential scanning calorimetry and mass photometry with molecular modelling. The thermal analysis resulted in a multistep denaturation profile, elucidating novel insights into the composite structural organization of the multi-domain protein LRRK2. Furthermore, LRRK2 shows a remarkable thermal stability, confirming its oligomeric nature. By using mass photometry, we could observe a monomer-dimer equilibrium which is altered by R1441G, a pathogenic variant within the Roc-COR interface. Most importantly, we could demonstrate that autophosphorylation induces LRRK2 monomerization, indicating a novel intramolecular feedback mechanism. Finally, we investigated the interaction of LRRK2 with its substrate, RAB10 by integrative computational modelling. The resulting models suggest that the monomeric form of LRRK2 is the favored protein conformation for the interaction with its substrate, leading to an increasing interest in the monomer-dimer equilibrium as a possible intervention point for the pathology.

31 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
BGBernd K. Gilsbach
Bernd K. Gilsbach
FHFranz Y. Ho
Franz Y. Ho
BRBenjamin Riebenbauer
Benjamin Riebenbauer
XZXiaojuan Zhang
Xiaojuan Zhang
GGGiambattista Guaitoli
Giambattista Guaitoli
CGChristian Johannes Gloeckner
Christian Johannes Gloeckner
The Parkinson’s Disease (PD)-linked protein Leucine Rich Repeat Kinase 2 (LRRK2) consists of seven domains, including a kinase and a Roc G domain. Despite the availability of several high-resolution structures, the dynamic regulation of its unique intramolecular domain stack is nevertheless still not well understood. By in-depth biochemical analysis, assessing the Michaelis-Menten kinetics of the Roc G domain, we have confirmed that LRRK2 has, similar to other Roco protein family members, a K M value of LRRK2 that lays within the range of the physiological GTP concentrations within the cell. Furthermore, the R1441G PD variant located within a mutational hotspot in the Roc domain showed an increased catalytic efficiency. In contrast, the most common PD variant G2019S, located in the kinase domain, showed an increased K M and reduced catalytic efficiency, suggesting a negative feedback mechanism from the kinase domain to the G domain. Autophosphorylation of the G1+2 residue (T1343) in the Roc P-loop motif is critical for this phosphoregulation of both the K M as well as the k cat values of the Roc-catalyzed GTP hydrolysis, most likely by changing the monomer-dimer equilibrium. The LRRK2 T1343A variant has a similar increased kinase activity in cells compared to G2019S and the double mutant T1343A/G2019S has no further increased activity suggesting that T1343 is crucial for the negative feedback in the LRRK2 signaling cascade. Together our data reveal a novel intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase dependent mechanism. Interestingly, PD mutants differently change the kinetics of the GTPase cycle, which might in part explain the difference in penetrance of these mutations in PD patients.

7 April 2019 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
RSRyan J. Schutte
Ryan J. Schutte
XZXiaojuan Zhang
Xiaojuan Zhang
NANan An
Nan An
DODavid Ostrov
David Ostrov
SVStanislav Vukmanović
Stanislav Vukmanović

1 December 2011
Verified
Journal Article
Closed access
PHPing Hu
Ping Hu
XZXiao-Yan Zhou
Xiao-Yan Zhou
DMDing-Yuan Ma
Ding-Yuan Ma
YSYun Sun
Yun Sun
XZXiao-Juan Zhang
Xiao-Juan Zhang
ZXzhengfeng xu
zhengfeng xu
To investigate potential mutation of the ASS1 gene in a male infant with acute citrullinemia type I. Genomic DNA was prepared from peripheral blood samples of the family members. Mutation analysis of the 14 ASS1 exons was carried out by PCR and direct DNA sequencing. A homozygous missense mutation of c.970G>A located in exon 13, which results in p.G324S, was identified in the child. Sequencing of the parents showed a heterozygous status for the same mutation. A missense mutation of c.970G>A in the ASS1 gene is responsible for the pathogenesis of the disease in the infant.